Indaptus Therapeutics (INDP) Projected to Post Quarterly Earnings on Wednesday

Indaptus Therapeutics (NASDAQ:INDP) is projected to post its quarterly earnings results before the market opens on Wednesday, May 14th. Analysts expect Indaptus Therapeutics to post earnings of ($0.41) per share for the quarter.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.03. On average, analysts expect Indaptus Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Indaptus Therapeutics Price Performance

Shares of INDP opened at $0.43 on Wednesday. Indaptus Therapeutics has a one year low of $0.43 and a one year high of $3.10. The company has a market cap of $6.89 million, a PE ratio of -0.25 and a beta of 1.49. The stock has a 50-day moving average of $0.60 and a 200-day moving average of $0.86.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.